| Date | Title | Description | |
|---|---|---|---|
| 24 Feb 2021 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
| 27 Nov 2020 | On business and financial situation | The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia | Download |
| 09 Jul 2020 | On business and financial situation | ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 08 May 2025 | Announcement of General Shareholders’ Meeting | The Company announces the call of its 2025 Ordinary General Shareholders' Meeting | Download |
| 04 Apr 2025 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the first quarter of 2025 | Download |
| 25 Feb 2025 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2024 annual report regarding remuneration of the members of the Board of Directors | Download |
| 25 Feb 2025 | Annual Financial Reports and Audit Reports | The Company submits the 2024 Annual Financial Report | Download |
| 07 Jan 2025 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the fourth quarter of 2024 | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 21 Feb 2013 | Información sobre resultados (2) | Download | |
| 21 Feb 2013 | Información sobre resultados | Download | |
| 21 Feb 2013 | Informe Anual de Gobierno Corporativo 2012 | Download | |
| 08 Nov 2012 | Información financiera intermedia | Download | |
| 08 Nov 2012 | Información sobre resultados | Download |